An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma

An Evaluation of the Tolerability and Feasibility of Combining 5-Amino-Levulinic Acid (5-ALA) with BCNU Wafers in the Surgical Management of Primary Glioblastoma

<i>Background</i> Glioblastoma (GBM) is the commonest primary malignant brain tumour in adults and effective treatment options are limited. Combining local chemotherapy with enhanced surgical resection using 5-aminolevulinic acid (5-ALA) could improve outcomes. Here we assess the safety...

Full description

Bibliographic Details
Main Authors: Colin Watts, Keyoumars Ashkan, Michael D. Jenkinson, Stephen J. Price, Thomas Santarius, Tomasz Matys, Ting Ting Zhang, Alina Finch, Peter Collins, Kieren Allinson, Sarah J. Jefferies, Daniel J. Scoffings, Athanasios Zisakis, Mark Phillips, Katharina Wanek, Paul Smith, Laura Clifton-Hadley, Nicholas Counsell
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
glioblastoma
5-aminolevulinic acid
BCNU wafers
chemoRT
feasibility trial
Online Access:https://www.mdpi.com/2072-6694/13/13/3241

Internet

https://www.mdpi.com/2072-6694/13/13/3241

Similar Items